Q4 EPS Estimates for Blueprint Medicines Boosted by Wedbush

Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Equities research analysts at Wedbush lifted their Q4 2024 EPS estimates for Blueprint Medicines in a research note issued to investors on Wednesday, October 30th. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will post earnings of ($0.66) per share for the quarter, up from their prior estimate of ($0.96). The consensus estimate for Blueprint Medicines' current full-year earnings is ($3.82) per share. Wedbush also issued estimates for Blueprint Medicines' Q1 2025 earnings at ($0.53) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($1.21) EPS.

BPMC has been the topic of several other research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $133.00 price target on shares of Blueprint Medicines in a research report on Wednesday. Barclays upped their price target on Blueprint Medicines from $75.00 to $105.00 and gave the company an "equal weight" rating in a research note on Monday, July 29th. UBS Group started coverage on Blueprint Medicines in a research report on Thursday, October 24th. They set a "neutral" rating and a $88.00 price objective for the company. Wells Fargo & Company decreased their target price on shares of Blueprint Medicines from $153.00 to $151.00 and set an "overweight" rating on the stock in a research report on Thursday. Finally, HC Wainwright reiterated a "buy" rating and set a $135.00 price target on shares of Blueprint Medicines in a research report on Thursday. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $120.39.

Blueprint Medicines Trading Up 3.6 %

BPMC stock traded up $3.19 during trading on Friday, reaching $90.70. 619,664 shares of the stock were exchanged, compared to its average volume of 694,702. The company has a current ratio of 3.71, a quick ratio of 3.65 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $5.75 billion, a price-to-earnings ratio of -42.99 and a beta of 0.58. The business has a 50 day moving average price of $88.79 and a 200-day moving average price of $98.39. Blueprint Medicines has a 1 year low of $56.74 and a 1 year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 118.86% and a negative net margin of 29.48%. The business had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. During the same quarter in the previous year, the firm earned ($2.20) EPS. The company's quarterly revenue was up 126.5% compared to the same quarter last year.

Insider Buying and Selling

In other Blueprint Medicines news, insider Philina Lee sold 41,913 shares of the stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $93.19, for a total value of $3,905,872.47. Following the sale, the insider now directly owns 34,729 shares of the company's stock, valued at approximately $3,236,395.51. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, insider Philina Lee sold 41,913 shares of the company's stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the completion of the transaction, the insider now directly owns 34,729 shares of the company's stock, valued at approximately $3,236,395.51. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Fouad Namouni sold 3,633 shares of the firm's stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total value of $324,499.56. Following the sale, the insider now directly owns 69,070 shares in the company, valued at $6,169,332.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.21% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC purchased a new stake in Blueprint Medicines in the first quarter valued at $218,000. SG Americas Securities LLC grew its stake in Blueprint Medicines by 117.6% during the 1st quarter. SG Americas Securities LLC now owns 11,865 shares of the biotechnology company's stock worth $1,126,000 after buying an additional 6,412 shares during the last quarter. Swiss National Bank increased its position in Blueprint Medicines by 0.4% during the first quarter. Swiss National Bank now owns 114,000 shares of the biotechnology company's stock worth $10,814,000 after buying an additional 500 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in Blueprint Medicines in the first quarter valued at approximately $474,000. Finally, Sei Investments Co. lifted its stake in Blueprint Medicines by 36.6% in the first quarter. Sei Investments Co. now owns 45,913 shares of the biotechnology company's stock valued at $4,355,000 after buying an additional 12,311 shares during the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.